Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-frequency versus standard-frequency intravesical BCG for high-grade non-muscle-invasive bladder cancer
NL-OMON45214Phase 3Active, not recruiting
- Sponsor
- European Association of Urology
- Start
- Dec 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bcg vaccine in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by European Association of Urology. Primary endpoint: Time to first recurrence. Started Dec 2013; status: active, not recruiting.
02
Drugs
bcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NL-OMON45214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45214.